NGIO Cancer treatment may look like this in the future: You take leronlimab to stop the spread, to stop metastasis and metastasized tumors. Surgery or radiation or CAR-T or other treatment to kill the principal tumor, and followed up with Generex's NGIO's cancer vaccination to prevent recurrence.
Which brings us to Generex, and we begin again with NGIO, which started life with 150 million shares; about another 20 million were added with the recently paid stock dividend, so that would be 170 million shares. Perhaps another 10 million will be added with the IPO. As a point of reference, INO which announced human trials beginning in April, has seen its market cap increase by a staggering $1 billion in the last 9 days to $1.4 billion. If NGIO were to have a vaccine in hand before their planned IPO, I think the pricing would be in the $7-$9 range. Without it, probably more in the $2 to $4 range.
It's cancer possibilities, which could be quite valuable, are completely in the shadow for now, but in the scenario I raised above, it may have a valuable role in the big picture of cancer treatment.
With China on lockdown, and now Italy on lockdown, nations are taking extreme action on the isolation front. Extreme hygiene, self-isolation, and anti-grouping behaviors may reduce the spread of this virus, and may reduce the need for vaccines, which is why work on this should continue, so that vaccines can be made quickly, especially for medical professionals.
While I expect shares will be sold in the IPO, money will start coming in from its virus work. It should be getting $6 million from China. And I presume the U.S. government will be paying such fees, and the countries of the European Union, and the UK, and so on. Given that they have already worked with SARS, which is a coronavirus, they have a leg up. Though if INO is doing human testing in April, it’s not that much of a leg up. With the March 4th collaboration with Epivax, they have probably improved their odds of developing a virus candidate sooner than later.
I expect some good news stories. More fundings. Grants. Whatever. Given GNBT’s previous extensive work in the area, there will probably be good results in studies, and finally, orders for vaccines doses. It could be very big. It’s a sleeper for now with INO and Moderna (MRNA) getting all the attention (and all the market cap gains).
Long time investors have been worn down with as they waited for stock dividends, which were halted for various reasons - potentially illegal selling of restricted stock, regulatory officials. But new investors will probably hit it just right.
But Generex (OTCQB:GNBT) has many other bets. My favorite technology of GNBT has always been the buccal delivery technology, what could be better for diabetic patients than a spritz inside the mouth? It’s a heck of a lot better than a needle. And that unit could ultimately be sold off for billions. Plus it has other possibilities: wound treatment, ulcerative colitis treatment, orthopedic products, medical services organization. My current feeling is to think of CEO Joseph Moscato as a biotech John Malone. Check the market cap. Weigh it. Divide the market cap by all of its possibilities, and it looks ridiculously low to me.
